Malawi

Praziquantel Donation Program

Merck KGaA’s Praziquantel Donation Program, in partnership with the World Health Organization (WHO), aims to fight schistosomiasis in Africa. Schistosomiasis is a parasitic worm disease that is the second most prevalent and devastating parasitic disease in tropical countries after malaria. Infection occurs when human skin comes into contact with fresh water contaminated by snails carrying the schistosome parasites, which migrate through the body and spread the infectious disease. It represents the 2nd most severe burden for African children after malaria, and is considered as one of the most neglected tropical diseases. The consequences of an infection are particularly serious for children, as schistosomiasis stunts growth and cognitive development and also lead to anemia. WHO reports more than 200 million infected people in Americas, Africa, the Middle East, Southeast and the Western Pacific.

ViiV Healthcare Collaborative Research Program for Resource-Poor Settings

ViiV Healthcare is committed to the development of new molecules that target unmet medical needs in HIV. The treatment of children with HIV/AIDS remains a significant unmet medical need and there is a pressing need for new medicines to tackle problems such as drug resistance, complex treatment regimens, and side effects associated with current treatments.

ViiV Healthcare Access to ARVs

In the Least Developed Countries and sub-Saharan Africa GlaxoSmithKline has offered its HIV/AIDS medicines at not-for-profit (nfp) prices since 2001. ViiV Healthcare will maintain this commitment, and will include the additional products in its portfolio. All of ViiV Healthcare's ARVs are now available at not-for-profit prices to public sector customers and not-for-profit organizations in all Least Developed Countries and all of sub-Saharan Africa - 64 countries in total.

Roche Children's Walk

The Roche Children's Walk (formerly the Global Roche Employee AIDS Walk) extended its scope to all vulnerable children in 2008. In 2008, 14,000 employees from 100 sites walked around five kilometers each to raise an estimated CHF 1.2 million, including the amount contributed by the company. While 35% was contributed via company affiliates to local children's charities, the balance was donated through Re&Act to Roche's long-term partners, the European Coalition of Positive People and UNICEF Switzerland, for their work in Malawi.

Regional Psychosocial Support Initiative

In Southern and East Africa, the Novartis Foundation aims to improve livelihoods and future prospects of children and adolescents affected by HIV/AIDS.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Pfizer Global Health Fellows

The Pfizer Global Health Fellows program utilizes the professional expertise of Pfizer employees through specialized volunteer assignments with nonprofit organizations to improve health care services for underserved communities around the world. Since 2003, more than 230 employees with a range of technical skills have served in 39 nations for 3-6 month assignments investing nearly 200,000 hours of skills-based service to help increase the capacity of nonprofits organizations providing health care to the underserved (in the reporting period, 54 Global Health Fellows were deployed).

Pfizer Diflucan Partnership

Pfizer created the Diflucan Partnership in 2000 to provide treatment for two AIDS-related fungal infections in developing countries. Since the program's inception, Pfizer has over provided USD 1.1 billion of products and its program partners distribute millions of Diflucan (fluconazole) treatments free of charge to governments and NGOs in 63 developing countries in Africa, Asia, the Caribbean and Latin America. Pfizer has also provided training and education materials to 20,000 healthcare professionals.

Pfizer - Azithromycin/chloroquine for Malaria

Pfizer, in partnership with Medicines for Malaria Venture (MMV) and London School of Hygiene and Tropical Medicine, is developing a fixed dose combination of azithromycin and chloroquine (AZCQ) for intermittent treatment of malaria in pregnant women (IPTp) in sub-Saharan Africa. IPTp is aimed at lowering the incidence of adverse pregnancy outcomes associated with malaria in pregnancy. Sulfadoxine/pyrimethamine (SP) is the current standard of care for IPTp in high transmission areas in Africa.

PATH Malaria Vaccine Initiative (MVI)

MVI works to link government, industry, and academia partners with field trial sites in malaria endemic countries as early as feasible in the development process.

Pages